Table 3.

Clinical utility comparison of IHC TPS and RNA-seq rank results

Prediction Method	Sensitivity	Specificity	PPV	NPV
Melanoma IHC ≥1%	31.3%	81.8%	55.6%	62.1%
Melanoma RNA-seq > 75	25.0%	93.2%	72.7%	63.1%
Melanoma IHC ≥1% & RNA-seq > 75	20.8%	94.6%	71.4%	64.8%
NSCLC IHC ≥1%	58.8%	60.6%	26.3%	71.4%
NSCLC IHC ≥50%	47.1%	84.5%	42.1%	87.0%
NSCLC RNA-seq > 75	58.8%	64.8%	28.6%	86.8%
NSCLC IHC ≥1% & RNA-seq > 75	63.6%	68.0%	30.4%	89.5%
NSCLC IHC ≥50% & RNA-seq > 75	46.2%	83.9%	37.5%	88.1%
RCC IHC ≥1%	28.6%	92.1%	40.0%	87.5%
RCC RNA-seq > 75	42.9%	84.2%	33.3%	88.9%
RCC IHC ≥1% & RNA-seq > 75	33.3%	93.9%	50.0%	88.6%

Sensitivity = TP/(TP + FN)

Specificity = TN/(TN + FP)

Positive predictive value (PPV) = TP/(TP + FP)

Negative predictive value (NPV) = TN/(TN + FN)